LDX Stock Overview
Develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lumos Diagnostics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.037 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.028 |
| Beta | 0.78 |
| 11 Month Change | -17.78% |
| 3 Month Change | 15.63% |
| 1 Year Change | -61.46% |
| 33 Year Change | -95.70% |
| 5 Year Change | n/a |
| Change since IPO | -97.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 8.8% | 0.9% | 1.7% |
| 1Y | -61.5% | 12.7% | 17.2% |
Return vs Industry: LDX underperformed the Australian Medical Equipment industry which returned 12.7% over the past year.
Return vs Market: LDX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| LDX volatility | |
|---|---|
| LDX Average Weekly Movement | 11.7% |
| Medical Equipment Industry Average Movement | 9.5% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: LDX's share price has been volatile over the past 3 months.
Volatility Over Time: LDX's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Doug Ward | lumosdiagnostics.com |
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers.
Lumos Diagnostics Holdings Limited Fundamentals Summary
| LDX fundamental statistics | |
|---|---|
| Market cap | AU$20.83m |
| Earnings (TTM) | -AU$12.40m |
| Revenue (TTM) | AU$16.06m |
1.3x
P/S Ratio-1.6x
P/E RatioIs LDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDX income statement (TTM) | |
|---|---|
| Revenue | US$11.13m |
| Cost of Revenue | US$4.57m |
| Gross Profit | US$6.56m |
| Other Expenses | US$15.16m |
| Earnings | -US$8.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 58.96% |
| Net Profit Margin | -77.19% |
| Debt/Equity Ratio | 0% |
How did LDX perform over the long term?
See historical performance and comparison